Cowen Starts Achaogen (AKAO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- S&P 500 ends higher as investors await tech earnings
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
William Blair Starts Achaogen (AKAO) at Outperform
April 7, 2014 4:26 PM EDTWilliam Blair initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $14.15 yesterday.
... MoreCredit Suisse Starts Achaogen (AKAO) at Outperform
April 7, 2014 7:31 AM EDTCredit Suisse initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $14.15 yesterday.
... MoreNeedham & Company Starts Achaogen (AKAO) at Buy
April 7, 2014 7:17 AM EDTNeedham & Company initiates coverage on Achaogen (NASDAQ: AKAO) with a Buy rating and a price target of $21.00.
Analyst Alan Car comments, "Lead drug plazomicin is under development for the treatment of infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). A Phase 3 trial... More
